奎硫平治疗阿尔茨海默病伴精神行为障碍对照研究

目的探讨奎硫平治疗阿尔茨海默病伴精神行为障碍患者的临床疗效和安全性。方法将66例阿尔茨海默病伴精神行为障碍患者随机分为两组各33例，研究组口服奎硫平治疗，对照组口服利培酮治疗，观察8w。于治疗前及治疗第2w、4w、8w末采用简明精神病量表评定临床疗效、副反应量表评定不良反应。结果治疗8w末，研究组有效率93．9％，对照组为90．9％；治疗2w末起两组简明精神病量表总分均较治疗前有显著下降，并随着治疗时间的延续呈持续性下降（P〈0．05或0．01）；治疗4w末研究组简明精神病量表焦虑抑郁因子分显著低于对照组（P〈0．05）；两组不良反应均轻微。结论奎硫平治疗阿尔茨海默病伴精神行为障碍效果显著，总体疗效、安全性与利培酮相当。

A control study of quetiapine in Alzheimer's disease accompanying behavior and mental disorders

OhjectiveTo explore the clinical efficacy and safety of quetiapine in the treatment of Alzheimer＇ s disease（AD） accompaning mental symptoms and behavior disorder. Methods Sixty-six AD patients with mental symptoms and behavior disorder were randomly assigned to two groups of 33 patients each, research group took orally quetiapine and control group did risperidone for 8 weeks. Clinical efficacies were assessed with the Brief Psychiatrie Rating Scale （BPRS） and adverse reactions with the Treament Emergent Symptoms Scale（TESS） before treatment and at the ends of the 2nd,4th and 8th week treatment. Resuits At the end of the 8th week, effective rates were 93. 9% in the research and 90. 9% in the control group respectively; since the end of the 2nd week, the total scores of both groups lowered more significantly compared with pretreatment and did continously along with treatment lasting（P〈0.05 or 0.01） ;at the end of the 4th week, anxiety-depression scores were significantly lower in the research than in the control group（P〈0.05） ; adverse reactions of both groups were mild. Conclusion Quetiapine has an evidnet effect in Alzheimer＇ s disease accompaning mental symptoms and behavior disorder, its global curative effect is equivalent to risperidone, and it has higher safety and better compliance and deserves clinical generalization and utilization.